Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban for bridging treatment of acute intracranial atherosclerotic vascular occlusion
ChiCTR1900022321Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tirofiban in cerebral arteriosclerosis and ischemic stroke (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Incidence of vascular re-occlusion. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
cerebral arteriosclerosisischemic stroke
Beyond the preview
Go deeper on ChiCTR1900022321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022321.